Advertisement

Breast Cancer Research and Treatment

, Volume 122, Issue 1, pp 35–43 | Cite as

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

  • Britta Weigelt
  • Alvin T. Lo
  • Catherine C. Park
  • Joe W. Gray
  • Mina J. Bissell
Preclinical study

Abstract

Development of effective and durable breast cancer treatment strategies requires a mechanistic understanding of the influence of the microenvironment on response. Previous work has shown that cellular signaling pathways and cell morphology are dramatically influenced by three-dimensional (3D) cultures as opposed to traditional two-dimensional (2D) monolayers. Here, we compared 2D and 3D culture models to determine the impact of 3D architecture and extracellular matrix (ECM) on HER2 signaling and on the response of HER2-amplified breast cancer cell lines to the HER2-targeting agents Trastuzumab, Pertuzumab and Lapatinib. We show that the response of the HER2-amplified AU565, SKBR3 and HCC1569 cells to these anti-HER2 agents was highly dependent on whether the cells were cultured in 2D monolayer or 3D laminin-rich ECM gels. Inhibition of β1 integrin, a major cell–ECM receptor subunit, significantly increased the sensitivity of the HER2-amplified breast cancer cell lines to the humanized monoclonal antibodies Trastuzumab and Pertuzumab when grown in a 3D environment. Finally, in the absence of inhibitors, 3D cultures had substantial impact on HER2 downstream signaling and induced a switch between PI3K-AKT- and RAS-MAPK-pathway activation in all cell lines studied, including cells lacking HER2 amplification and overexpression. Our data provide direct evidence that breast cancer cells are able to rapidly adapt to different environments and signaling cues by activating alternative pathways that regulate proliferation and cell survival, events that may play a significant role in the acquisition of resistance to targeted therapies.

Keywords

Breast cancer cell lines Drug response Targeted therapy 3D cell culture HER2 signaling 

Abbreviations

lrECM

Laminin-rich extracellular matrix gel

2D

Two-dimensional

3D

Three-dimensional

HER2

Human epidermal growth factor receptor type 2

EGFR

Epidermal growth factor receptor

Notes

Acknowledgments

We thank G. Lee (Genentech, Inc, South San Francisco) for discussions, W.-L. Kuo and N. Bayani for support with the cell lines, P. Kenny (Albert Einstein College, New York) and J.S. Reis-Filho (Breakthrough Breast Cancer Research Centre, London) for critical reading of the manuscript.

BW was supported by a postdoctoral fellowship of the Dutch Cancer Society. The work from MJB's laboratory was supported by grants from the U.S. Department of Energy, Office of Biological and Environmental Research (DE-AC02-05CH1123), a Distinguished Fellow Award, Low Dose Radiation Program, Office of Health and Environmental Research (03-76SF00098), National Cancer Institute awards 5 R01CA064786, R01CA057621, U54CA126552 and U54CA112970 and by U.S. Department of Defense (W81XWH0810736). CP was supported by grants from the American Cancer Society (RSG-07-1110-01-CCE) and National Institutes of Health (R01CA124891); JWG by the Director, Office of Science, Office of Biological & Environmental Research, of the US Department of Energy under Contract No. DE-AC02-05CH1123, by the National Institutes of Health, National Cancer Institute grants P50CA58207 and U54CA112970, and by the SmithKline Beecham Corporation grant.

Supplementary material

10549_2009_502_MOESM1_ESM.pdf (70 kb)
Supplementary material 1 (PDF 69 kb)

References

  1. 1.
    Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1:46–54CrossRefPubMedGoogle Scholar
  2. 2.
    Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ (1989) Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development 105:223–235PubMedGoogle Scholar
  3. 3.
    Petersen OW, Rønnov-Jessen L, Howlett AR, Bissell MJ (1992) Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci U S A 89:9064–9068CrossRefPubMedGoogle Scholar
  4. 4.
    Schmeichel KL, Weaver VM, Bissell MJ (1998) Structural cues from the tissue microenvironment are essential determinants of the human mammary epithelial cell phenotype. J Mammary Gland Biol Neoplasia 3:201–213CrossRefPubMedGoogle Scholar
  5. 5.
    Bissell MJ, Rizki A, Mian IS (2003) Tissue architecture: the ultimate regulator of breast epithelial function. Curr Opin Cell Biol 15:753–762CrossRefPubMedGoogle Scholar
  6. 6.
    Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137:231–245CrossRefPubMedGoogle Scholar
  7. 7.
    Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, Bissell MJ (1998) Reciprocal interactions between beta 1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 95:14821–14826CrossRefPubMedGoogle Scholar
  8. 8.
    Liu H, Radisky DC, Wang F, Bissell MJ (2004) Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol 164:603–612CrossRefPubMedGoogle Scholar
  9. 9.
    Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1:84–96CrossRefPubMedGoogle Scholar
  10. 10.
    Anders M, Hansen R, Ding RX, Rauen KA, Bissell MJ, Korn WM (2003) Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci U S A 100:1943–1948CrossRefPubMedGoogle Scholar
  11. 11.
    Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ (2002) Beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2:205–216CrossRefPubMedGoogle Scholar
  12. 12.
    Serebriiskii I, Castelló-Cros R, Lamb A, Golemis EA, Cukierman E (2008) Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol 27:573–585CrossRefPubMedGoogle Scholar
  13. 13.
    Pickl M, Ries CH (2009) Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28:461–468CrossRefPubMedGoogle Scholar
  14. 14.
    Bissell MJ, Weaver VM, Lelièvre SA, Wang F, Petersen OW, Schmeichel KL (1999) Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res 59:1757–1763sPubMedGoogle Scholar
  15. 15.
    Yamada KM, Cukierman E (2007) Modeling tissue morphogenesis and cancer in 3D. Cell 30:601–610CrossRefGoogle Scholar
  16. 16.
    Pampaloni F, Reynaud EG, Stelzer EH (2007) The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8:839–845CrossRefPubMedGoogle Scholar
  17. 17.
    Weigelt B, Bissell MJ (2008) Unraveling the microenvironmental influences on normal mammary gland and breast cancer. Semin Cancer Biol 18:311–321CrossRefPubMedGoogle Scholar
  18. 18.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRefPubMedGoogle Scholar
  19. 19.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684CrossRefPubMedGoogle Scholar
  20. 20.
    Nahta R, Esteva FJ (2007) Trastuzumab: triumphs and tribulations. Oncogene 26:3637–3643CrossRefPubMedGoogle Scholar
  21. 21.
    Weaver VM, Fischer AH, Peterson OW, Bissell MJ (1996) The importance of the microenvironment in breast cancer progression: recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay. Biochem Cell Biol 74:833–851CrossRefPubMedGoogle Scholar
  22. 22.
    Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4:359–365CrossRefPubMedGoogle Scholar
  23. 23.
    Briand P, Petersen OW, Van Deurs B (1987) A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium. In Vitro Cell Dev Biol 23:181–188CrossRefPubMedGoogle Scholar
  24. 24.
    Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515–527CrossRefPubMedGoogle Scholar
  25. 25.
    Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127CrossRefPubMedGoogle Scholar
  26. 26.
    Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221–9230CrossRefPubMedGoogle Scholar
  27. 27.
    Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285:1028–1032CrossRefPubMedGoogle Scholar
  28. 28.
    White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U, Muller WJ (2004) Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6:159–170CrossRefPubMedGoogle Scholar
  29. 29.
    Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ (2006) Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66:1526–1535CrossRefPubMedGoogle Scholar
  30. 30.
    Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ (2008) Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res 68:4398–4405CrossRefPubMedGoogle Scholar
  31. 31.
    Yarden Y, Sliwkowski MX (2001) The Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137CrossRefPubMedGoogle Scholar
  32. 32.
    Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, Birnbaum D (2007) ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene 26:7163–7169CrossRefPubMedGoogle Scholar
  33. 33.
    Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65:10992–11000CrossRefPubMedGoogle Scholar
  34. 34.
    Dhiman HK, Ray AR, Panda AK (2005) Three-dimensional chitosan scaffold-based MCF-7 cell culture for the determination of the cytotoxicity of tamoxifen. Biomaterials 26:979–986CrossRefPubMedGoogle Scholar
  35. 35.
    Xu R, Nelson CM, Muschler JL, Veiseh M, Vonderhaar BK, Bissell MJ (2009) Sustained activation of STAT5 is essential for chromatin remodeling and maintenance of mammary-specific function. J Cell Biol 184:57–66CrossRefPubMedGoogle Scholar
  36. 36.
    Schatzmann F, Marlow R, Streuli CH (2003) Integrin signaling and mammary cell function. J Mammary Gland Biol Neoplasia 8:395–408CrossRefPubMedGoogle Scholar
  37. 37.
    Boudreau N, Sympson CJ, Werb Z, Bissell MJ (1995) Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267:891–893CrossRefPubMedGoogle Scholar
  38. 38.
    Nelson CM, Bissell MJ (2006) Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22:287–309CrossRefPubMedGoogle Scholar
  39. 39.
    Bissell MJ, Kenny PA, Radisky DC (2005) Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 70:343–356CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  1. 1.Life Sciences Division, Lawrence Berkeley National LaboratoryUniversity of California BerkeleyBerkeleyUSA
  2. 2.Cancer Research UK London Research InstituteLondonUK
  3. 3.Department of Radiation OncologyUniversity of California Comprehensive Cancer CenterSan FranciscoUSA

Personalised recommendations